Results 101 to 110 of about 396,648 (275)

Characterization of Immune Responses to RBD‐SD1 Nanoparticle Vaccines Derived From ACE2‐Capable HKU5‐CoV‐2, NeoCoV, and HKU5 Merbecoviruses

Biotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles presenting HKU5, NeoCoV, and HKU5‐CoV‐2 RBD‐SD1 induced strong, cross‐reactive IgG responses in immunized mice. The surrogate virus neutralization test demonstrated strong activity in sera from homologous vaccination. ABSTRACT Recent discoveries of merbecoviruses such as HKU5, NeoCoV, and HKU5‐CoV‐2 that use angiotensin ...
Peter J. Halfmann, Jeong Soo Lee, Augustine Duffy, Tong Wang, Bingcheng Huang, James Z. Kurdi, Ajay Inampudi, Natasha Chen, Elizabeth Frimpong, Carmen Rai, Yoshihiro Kawaoka, Ravi S. Kane   +11 more
wiley   +1 more source

The Efficiency of a Group-Specific Mandated Benefit Revisited: The Effect of Infertility Mandates [PDF]

This paper examines the labor market effects of state health insurance mandates that increase the cost of employing a demographically identifiable group.
Joanna N. Lahey
core  

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Digital Transformation of Medicines Regulation in Africa—Perspectives from a Stakeholder Convening

Clinical Pharmacology &Therapeutics, EarlyView.
Regulatory authorities worldwide are developing strategies to integrate artificial intelligence (AI) into the lifecycle of health products, technologies, and medicines. While regulators share goals of improving efficiency, strengthening decision‐making, and protecting public health, their approaches differ according to institutional structures ...
Christelna Reyneke, Boitumelo Semete‐Makokotlela, Varnika Singh, Khanyisile Nkuku, Madelein Terblanche, Ezekiel T Mukanga, Nancy Ngum, Kudakwashe Dandajena, McNeil Chimus Mhango, Paulyne Wairimu, John Mwangi, Dominique Lagrave, Goonaseelan (Colin) Pillai   +12 more
wiley   +1 more source

An open repository of COVID-19 vaccine mandate studies with a worked scoping review of quasi-experimental evidence

npj Vaccines
Vaccine mandates were widely implemented against COVID-19, and a large and multidisciplinary literature has emerged as a result, covering fields such as epidemiology, economics, ethics, and law.
Fabio I. Martinenghi, Tanka Prashad Ojha, Amy Thomasson, Bianca Devsam, Shevaun Drislane, Sophie Vasiliadis, Chiara Berardi, Aregawi Gebremariam, Alessia Dipalma, Teresa Gavaruzzi, Jeremy K. Ward, Francesco Paolucci, Margie Danchin, Mesfin Genie, Katie Attwell, Christopher C. Blyth   +15 more
doaj   +1 more source

A British Pharmacological Society Position Statement on Medications in Pregnancy and Lactation

British Journal of Clinical Pharmacology, EarlyView.
Agnesa Mustafa, Cleodie C. Swire, Reya V. Shah, Bernadette Jenner, Rory H. McLean, Muhammad Shamsher Ahmed, Adrie Bekker, Julia Zöllner, Rachel K. Scott, Robert R. Bies, Sara K. Quinney, Dagan O. Lonsdale, Emma Forton Magavern, Catriona Waitt, Anita Banerjee   +14 more
wiley   +1 more source

Special Populations in Pivotal Clinical Trials: Eligibility and Supporting Evidence for Exclusion in EMA‐Authorised Medicines

Clinical Pharmacology &Therapeutics, EarlyView.
Evidence on the efficacy and safety of medicines supporting marketing authorization is largely derived from randomized controlled trials, yet these trials often exclude populations likely to use the medications in clinical practice. This study assessed eligibility of special populations, defined as pregnant and breast‐feeding individuals, elderly ...
Maja J. Jørgensen, Débora D. Gräf, Christine E. Hallgreen   +2 more
wiley   +1 more source

Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis

, 2013
Improvement to the immunogenicity of DNA vaccines was evaluated in a Mycobacterium tuberculosis (MTB) infection mouse model examining the combined effects of nonlytic Fc-fused IL-7 DNA (IL-7-nFc) and Flt3-ligand fused Mtb32 (F-Mtb32) DNA.
조상래
core   +1 more source

The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine [PDF]

, 2012
This paper estimates the marginal willingness-to-pay for attributes of a hypothetical HIV vaccine using discrete choice modeling. We use primary data from 326 respondents from Bangkok and Chiang Mai, Thailand, in 2008–2009, selected using purposive ...
Newman, Peter A., Newman, PA, P. A. Newman, S. Roungprakhon, Newman, P.A., Cameron, MP, Scarpa, R., Scarpa, R, Scarpa, Riccardo, Roungprakhon, S, Cameron, Michael P., Cameron, Michael Patrick, Cameron, M.P., Roungprakhon, S., Roungprakhon, Surachet, M. P. Cameron   +15 more
core   +1 more source

Assessing Sustainability Performance in the Life Insurance Industry: An Integrated Sustainability Balanced Scorecard Framework Under q‐Rung Orthopair Fuzzy Information

Corporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT Assessing the sustainability performance of life insurers has become increasingly important, as long‐term competitiveness depends not only on financial soundness but also on environmental, social, organizational, and governance‐related capabilities.
Özcan Işık, İbrahim Adalar
wiley   +1 more source